Login / Signup

Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.

Tino SeverinsenJens Jakob ThuneHelga Lillian GudmundsdottirChristoffer Rasmus VissingKasper IversenCarolyn Yung HoHenning BundgaardAnna Axelsson Raja
Published in: American heart journal (2023)
Despite applying the potentially more sensitive composite z-score endpoint as in the VANISH trial, no statistically significant benefits from the use of losartan compared to placebo could be detected at 12-month follow-up in patients with overt HCM participating in the INHERIT trial.
Keyphrases
  • hypertrophic cardiomyopathy
  • phase iii
  • left ventricular
  • study protocol
  • angiotensin converting enzyme
  • angiotensin ii
  • phase ii
  • clinical trial
  • open label
  • double blind
  • randomized controlled trial
  • placebo controlled